Long-term Follow-up of Patients With Sanfilippo Type A Syndrome Who Have Previously Been Treated in the P1-SAF-301 Clinical Study Evaluating the Tolerability and Safety of the Intracerebral Administration of SAF-301 [EXTENSION OF 700240974]
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2017
Price : $35 *
At a glance
- Drugs SAF 301 (Primary)
- Indications Mucopolysaccharidosis III
- Focus Adverse reactions
- Sponsors LYSOGENE
- 19 Jun 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
- 17 Jan 2017 Planned primary completion date changed from 1 May 2016 to 1 May 2017.